Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 11/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 3/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724396 | 0.93 | NT5E (0.40) | P2RY1NT5E | |
| SCHEMBL19765803 | 0.92 | RNASEL (0.43) | P2RY1P2RY2P2RX1P2RX3ENPP1 | |
| SCHEMBL19765779 | 0.91 | RNASEL (0.42) | P2RY1P2RY2P2RX1P2RX3ENPP1 | |
| SCHEMBL20724406 | 0.88 | P2RY1 (0.43) | P2RY1P2RY2P2RX1P2RX3ENPP1 | |
| SCHEMBL20724608 | 0.87 | CYP2C19 (0.36) | NT5E | |
| SCHEMBL19765821 | 0.84 | P2RY1 (0.39) | P2RY1NT5ERNASEL | |
| SCHEMBL16368336 | 0.83 | KRAS (0.53) | P2RY2P2RY6NT5E | |
| SCHEMBL19986613 | 0.83 | KRAS (0.53) | P2RY2P2RY6NT5E | |
| SCHEMBL19765997 | 0.83 | TMIGD3 (0.41) | — | |
| SCHEMBL16490110 | 0.82 | P2RX1 (0.57) | P2RY1P2RY2P2RX1P2RX3P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | Atea Pharmaceuticals, Inc. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | MTAP, NSUN2, PNP | P2RY1 207/4885P2RY2 171/4885P2RX1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.